Strata Critical Medical, Inc. Earnings Recaps
Q2 2026
Aug 6, 2026
The stock gained 5.4% after reporting better-than-expected growth in the clinical business, driven by strong 23.8% sequential growth in Transplant Clinical revenue and expanding gross margins, which outweighed softness in the Logistics segment.
Key takeaways
- Clinical revenue increased 15.1% sequentially on an organic basis, fueled by 23.8% growth in Transplant Clinical services.
- Clinical gross margins improved to 26.1% in Q2 from 25% in Q1, enhancing overall profitability.
- Logistics revenue faced headwinds due to significantly reduced flying volumes with one nonexclusive customer, impacting about 3% of segment revenue; volume reduction expected to impact full Q3 before recovery.
- Operating cash flow was $5.7 million with free cash flow of $2.9 million, marking the second consecutive quarter of positive cash generation.
- Closed three bolt-on acquisitions expanding clinical capabilities and geographic reach, strengthening future growth and margin profile while advancing capital deployment ahead of plan.
Q1 2026
May 7, 2026
Strata’s shares rallied 10.8% following a quarter marked by robust revenue growth driven by Logistics and new Clinical business lines, alongside positive signs of improving cash flow and an active M&A pipeline that exceeded investor expectations.
Key takeaways
- Reported 87% year-over-year revenue growth, led by 32% organic growth in Logistics and strong contributions from the new Clinical segment.
- Generated operating and free cash flow before aircraft acquisitions for the first time this quarter, indicating improved earnings quality.
- Announced a new acquisition of Ohio Valley Perfusion Associates, aligned with a broader M&A strategy targeting fragmented markets with mid-single-digit EBITDA multiples.
- Expanded logistics footprint with a new base in Chicago and a total fleet of 10 owned aircraft plus 35 dedicated, enhancing national service coverage.
- Industry trends toward increased adoption of NRP and third-party surgical recovery have offset declines in donor volume, supporting demand for Strata’s integrated platform.